VEA
DYN icon

Virtus ETF Advisers’s Dyne Therapeutics DYN Stock Holding History

Virtus ETF Advisers’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,776
Closed -$65.4K – 533
2024
Q4 		$65.4K Buy
2,776
+40
+1% +$1.18K 0.03% 414
2024
Q3 		$98.3K Buy
2,736
+49
+2% +$1.95K 0.05% 380
2024
Q2 		$94.8K Sell
2,687
-4,639
-63% -$135K 0.05% 337
2024
Q1 		$208K Sell
7,326
-507
-6% -$11.5K 0.11% 245
2023
Q4 		$104K Sell
7,833
-139
-2% -$1.36K 0.07% 343
2023
Q3 		$71.4K Sell
7,972
-797
-9% -$8.59K 0.04% 381
2023
Q2 		$98.7K Buy
8,769
+1,434
+20% +$16.9K 0.06% 389
2023
Q1 		$84.5K Sell
7,335
-2,815
-28% -$36.6K 0.05% 378
2022
Q4 		$118K Buy
+10,150
New +$117K 0.06% 425

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtus ETF Advisers's DYN Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Dyne Therapeutics (DYN) in Q1 2025, closing a stake of 2,776 shares — an estimated $65.4K sold.

Virtus ETF Advisers first reported a position in DYN in Q4 2022 and held it in 9 quarters. The position peaked at $208K in Q1 2024. 205 funds tracked by Wall St. Rank hold DYN as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Dyne Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,776 Dyne Therapeutics shares in Q1 2025, an estimated $65.4K.
  • Virtus ETF Advisers first reported a position in Dyne Therapeutics in Q4 2022 and held it in 9 quarters.
  • Virtus ETF Advisers's Dyne Therapeutics position peaked at $208K in Q1 2024.
  • 205 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.